Please assess the completion status of the following clinical trial:

Trial Title: Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-70 years~* increased risk for infections - at least 4 cold episodes within 12 months~* commitment to adhere to their accustomed diet and physical activity~* women of child-bearing potential have to agree to use appropriate birth control methods~* written consent of the subject to participate is a prerequisite for study participation~Exclusion Criteria:~* acute / chronic upper airways disease~* chronic cough of any origin~* acute / chronic lower airways disease~* any allergic reaction that may influence the study outcome (e.g. acute/chronic rhinitis)~* history of nasal reconstructive surgery~* presence of nasal ulcers or nasal polyps~* severe nasal septum deviation or other condition that could cause nasal obstruction~* congenital or acquired immunodeficiency disease (e.g. HIV infection)~* severe organ or systemic diseases~* body temperature above 37.5°C~* suspected swine flu or influenza~* vaccination against influenza or swine flu within 3 months prior to study start~* stomach/gastrointestinal diseases~* sleep disorder~* psychiatric disorders~* known sensitivity to the ingredients of the investigational product~* intake of products that may influence the study outcome within the last 14 days prior to study start and during the study~* analgesics , antibiotics or decongestant nose drops/spray, unless they are used as rescue medications~* pregnancy or nursing~* alcohol / drug abuse~* simultaneous participation in another clinical trial or participation in a clinical trial within the last 30 days~* insufficient compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- IQP-AS-105 (Type: ACTIVE_COMPARATOR): One tablet daily
- Placebo (Type: PLACEBO_COMPARATOR): One tablet daily

Based on this trial design, predict the completion outcome and termination type (if applicable).